The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

The first mpox vaccine approved by the WHO is MVA-BN, made by Bavarian Nordic A/S. It was approved for emergency use and can be used "off-label" in infants, children and adolescents as well as in ...

Bavarian Nordic’s Mpox vaccine met with the World Health Organization's approval on Monday for use among adolescents aged between 12-17. This age bracket is considered to be highly vulnerable to ...